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Introduction: Human circulating monocytes express the calcium-sensing receptor (CaSR) and are involved in
atherosclerosis. This study investigated the potential association between vascular calcification in rheumatoid
arthritis (RA) and CaSR expression in circulating monocytes.
Methods: In this cross-sectional study, 50 RA patients were compared to 25 control subjects matched for age and
gender. Isolation of peripheral blood mononuclear cells and flow cytometry analysis were performed to study the
surface and total CaSR expression in circulating monocytes. Coronary artery calcium (CAC) and abdominal aortic
calcification (AAC) scores were evaluated by computed tomography and an association between these scores and
the surface and/or total CaSR expression in circulating monocytes in RA patients was investigated.
Results: The two groups were similar in terms of age (RA: 60.9 ± 8.3 years, versus controls: 59.6 ± 5.3 years) and
gender (RA: 74.0% females versus 72.0% females). We did not find a higher prevalence and greater burden of CAC
or AAC in RA patients versus age- and gender-matched controls. When compared with control subjects, RA patients
did not exhibit greater total CaSR (101.6% ± 28.8 vs. 99.9% ± 22.0) or surface CaSR (104.6% ± 20.4 vs. 99.9% ± 13.7)
expression, but total CaSR expression in circulating monocytes was significantly higher in RA patients with severe
CAC (Agatston score ≥200, n = 11) than in patients with mild-to-moderate CAC (1 to 199, n = 21) (P = 0.01).
Conclusions: This study demonstrates for the first time that total CaSR expression in human circulating monocytes
is increased in RA patients with severe coronary artery calcification.Introduction
Patients with rheumatoid arthritis (RA) are exposed to a
substantially increased risk of cardiovascular events (es-
pecially coronary heart disease) and death [1-5]. Fur-
thermore, the increased risk for cardiovascular disease
cannot be fully explained by traditional cardiovascular
risk factors [1,2]. Moreover, stratification tools such as
the Framingham risk score [6], widely used in primary* Correspondence: julienpaccou@yahoo.fr
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unless otherwise stated.prevention in the general population, are less suitable
in RA patients [7,8]. A growing body of evidence sug-
gests that nontraditional risk factors such as chronic in-
flammation and RA features have a pivotal role in
accelerated atherosclerosis and the increased cardiovas-
cular disease risk [9-11].
Vascular calcification is commonly used as a subclin-
ical marker of atherosclerosis and has been linked to
increased all-cause mortality, cardiovascular mortality
and coronary events [12]. Moreover, patients with RA
are known to develop early-onset, widespread calcification
in various vascular beds [13-15]. This is consistent with
the concept whereby inflammation promotes atheroscler-
osis and vascular calcification [16]. Cardiovascular diseaseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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need to focus on further delineating the underlying bio-
logical mechanisms involved in vascular calcification, and
developing and evaluating novel biomarkers.
Patients with chronic kidney disease (CKD) are also at
a particularly high risk for cardiovascular disease. The
prevalence and severity of vascular calcification is corre-
lated with disease stage in CKD and considered as a
cardiovascular risk marker. Vascular calcification is the
result of both passive and active processes that involve a
variety of factors and proteins [17]. Originally cloned from
bovine parathyroid glands, the calcium-sensing receptor
(CaSR) has been studied for its role in mediating systemic
calcium homeostasis. However, the CaSR has also been
shown to have pleiotropic actions on cells, including
modification of cellular proliferation, differentiation, and
apoptosis [18-20]. Interestingly, the CaSR was expressed
on vascular smooth muscle cells (VSMCs) and its expres-
sion was decreased in the arteries of patients with CKD
compared to controls [21]. Moreover, modulation of CaSR
expression on VSMCs in CKD by calcimimetic agents
(R-568) was demonstrated to effectively delay progression
of vascular calcification and atherosclerosis in uremic apo-
lipoprotein E-deficient mice [22].
However, in patients with RA, the role of CaSR expres-
sion remains to be investigated. Monocytes/macrophages
are known to play a crucial role in the pathogenesis of ath-
erosclerosis and a considerable focus has been placed on
their precursor, circulating monocytes as predictors of car-
diovascular disease [21-23]. Intriguingly, CaSR expression
has been demonstrated in human circulating monocytes
and extracellular calcium has been shown to be a chemo-
kinetic agent for human circulating monocytes [24-26].
Moreover, monocytes/macrophages also modulate vascu-
lar calcification in vitro [27]. It seemed important to clarify
the role of the CaSR expressed in circulating monocytes in
the pathological process leading to vascular calcification
in patients with RA.
In a previous study, we provided evidence indicating
that CaSR expression can be measured by flow cytometry
in human circulating monocytes and its measurement
would be potentially useful in certain clinical situations, in
which changes in CaSR expression could be expected [28].
The present study was therefore designed to explore the
potential association between vascular calcification in RA
and CaSR expression in human circulating monocytes.
Methods
Study design
In this cross-sectional study, 50 RA patients were com-
pared to 25 non-RA control subjects matched for age and
gender. Control subjects were enrolled from a pool of vol-
unteers set up by the general Clinical Center of Amiens
University Hospital, France. RA patients were enrolledfrom the Rheumatology Outpatients Department of
Amiens University Hospital, France. All subjects gave
their written informed consent, and the study was approved
by the University Hospital ethics committee (Comité de
Protection des Personnes Nord-Ouest 2) (Number 2012-
A00323-40) and l’Agence Française de Sécurité Sanitaire
des Produits de Santé.
Study population
Inclusion criteria for this study were as follows: pres-
ence of the 2010 American College of Rheumatology/
European League Against Rheumatism classification
criteria for RA, age 45 to 80 years and capacity to
understand the goals of the study. Only anti-TNFα was
allowed as current and/or previous biological disease-
modifying anti-rheumatic drugs (bDMARDs). Exclusion cri-
teria were as follows: self-reported or physician-diagnosed
history of myocardial infarction, heart failure, coronary ar-
tery revascularization, stroke events, peripheral vascular
disease, abdominal aortic aneurysm and current atrial fib-
rillation, weight exceeding 150 kg, inflammatory diseases
other than RA. Controls did not meet the classification
criteria for RA or any other inflammatory disease.
Study protocol
Information was obtained by means of a structured
interview, physical examination, laboratory tests, and
electron-beam computed tomography (CT), and the med-
ical records of all patients were reviewed. Demographic
and clinical characteristics and traditional cardiovascular
risk factors were collected. The general cardiovascular risk
profile was estimated by the Framingham risk scores
(FRS) [6]. In RA patients, duration of disease was recorded
and disease activity was measured using the disease activ-
ity score based on evaluation of 28 joints (DAS28). The
DAS28 is a validated composite index containing a 28-
joint count for tenderness (TJC), a 28-joint count for
swelling (SJC), erythrocyte sedimentation rate (ESR) or
high-sensitivity C-reactive protein (hs-CRP), and the pa-
tient’s overall assessment of well-being (range 0 to 100).
DAS28 was adjusted on hs-CRP. The health assessment
questionnaire (HAQ) was also filled in. Current and pre-
vious biological and conventional synthetic DMARDs
used for RA were determined both from information pro-
vided by the patients and from medical records. Concomi-
tant medications, such as NSAIDs and corticosteroids,
were also recorded.
Laboratory parameters
RA patients and controls were required to fast overnight
prior to collection of blood for determination of complete
blood cell count as well as measurement of serum calcium
(Ca), phosphate (Ph), protein (Pt), creatinine (Scr) and gly-
cemia. Serum intact parathyroid hormone (iPTH 1-84)
Paccou et al. Arthritis Research & Therapy 2014, 16:412 Page 3 of 9
http://arthritis-research.com/content/16/4/412was determined by a chemiluminometric immunoassay
(Liaison N-tact PTH CLIA; Diasorin, Stillwater, MN,
USA). Serum 25 OH vitamin D level was determined
(LIAISON™ 25 OH Vitamin D Total Assay; Diasorin).
Corrected calcium levels were calculated for each subject.
Estimated glomerular filtration rate (GFR) was calculated
using the modification of diet in renal disease (MDRD)
formula (ml/min). Total cholesterol, high-density lipo-
protein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol and triglycerides were determined. The Wes-
tergren ESR was used and hs-CRP values were analyzed in
an onsite biochemistry laboratory using standard autoana-
lyzer techniques. The presence of rheumatoid factor (RF)
as well as anti-cyclic citrullinated peptide antibody (anti-
CCP) was only determined for RA patients. IL6 and TNFα
were assayed (eBiosciences™ hIL6 total enzyme-linked im-
munosorbent assay (ELISA) BMS213/2 kit and hTNFα
total ELISA BMS2034 kit; Vienna, Austria). As indicates
in the manufacturer’s kit instruction, the limits of detec-
tion of hTNFα and hIL6 are 5.0 pg/ml and 0.92 pg/ml.
Traditional cardiovascular risk factors
Subjects were considered to present hypertension when
they were taking antihypertensive agents or when they
had a systolic blood pressure ≥140 mmHg and/or dia-
stolic pressure ≥90 mmHg. Blood pressure was deter-
mined as the average of two measurements obtained at
an interval of five minutes after subjects had been rest-
ing in the supine position for at least 10 minutes. Dia-
betes mellitus was defined as the presence of any of the
following: (i) fasting blood glucose ≥1.26 g/l (7 mmol/l),
(ii) current use of oral hypoglycemic agents and/or use
of insulin. Smoking status was recorded as self-reported
current smokers. Height and weight were measured and
body mass index (BMI) was calculated as weight/height2
(kg/m2). A family history of coronary artery disease was
defined as a first-degree relative with myocardial infarc-
tion before the age of 55 years in men, and before the
age of 65 years in women. Patients and controls were
considered to have hypercholesterolemia when they self-
reported a previous diagnosis of hypercholesterolemia,
and/or use of lipid-lowering drugs.
Study outcomes
This study evaluated (i) coronary artery calcification
(CAC) and abdominal aortic calcification (AAC) scores
and (ii) surface and total CaSR expression in human cir-
culating monocytes.
CAC and AAC scores
In order to quantify the presence and extent of vascular
calcification, each patient underwent a nonenhanced 64-
slice CT scan (Discovery CT750 HD; GE Healthcare,
Milwaukee, WI, USA). A prospective electrocardiogram(ECG)-gated sequential scan of the whole heart was per-
formed to measure CAC with the following parameters:
collimation of 64 × 0.625 mm, slice thickness of 2.5 mm,
gantry rotation time of 350 ms, tube voltage of 120 kV
and a tube current of 200 mA. CAC scores were calcu-
lated according to the Agatston method, using CAC-
scoring software (Smart Score 4.0; GE Healthcare). CAC
scores were defined as none (CAC = 0) mild-to-moderate
(CAC = 1 to 199) or severe (CAC ≥200). The limit of CAC
severity score was set at 200 because a calcium score ≥200
among patients ≥50 years old provided strong evidence
that patients of either sex had obstructive coronary artery
disease (CAD) [29]. Moreover, the mean CAC score for
RA patients was almost 200. Abdominal aorta was evalu-
ated without ECG gating. The start of volume acquisition
was placed at the level of the diaphragmatic aortic hiatus
and the end was placed below the aortic bifurcation. Scan-
ning parameters were: collimation of 64 × 0.625 mm, slice
thickness of 0.625 mm, a pitch of 1, gantry rotation time
of 500 ms, tube voltage of 120 kV and tube current of
300 mA. Image sets for all patients were analyzed with a
commercially available external workstation (Advantage
Windows 4.6; GE Healthcare). The abdominal aorta was
segmented manually on three-dimensional MIP images.
In order to reduce errors due to noise, a cutoff of 160 HU
was applied. The total calcification volume was calculated
as the sum of all voxels in the remaining volume. The ab-
dominal aorta calcification CT scan score was calculated
as follows: ((total calcification volume)/(aortic wall surface
area) × 100)) [30].
Surface and total CaSR expression in human circulating
monocytes
Isolation of peripheral blood mononuclear cells was per-
formed for flow cytometry analysis. For each participant,
3 ml of blood was mixed with 22 ml of PBS-0.5%BSA
(mononuclear cells were isolated by density gradient cen-
trifugation); 25 ml of diluted blood were carefully added
to 10 ml of Lymphosep™, and the tubes were then centri-
fuged for 25 minutes at room temperature and 1800 g.
After centrifugation, the interphase containing mono-
nuclear cells was carefully aspirated and the cells were
washed using 5 ml of PBS-0.5%BSA before being centri-
fuged for five minutes at room temperature (1800 g). Cells
were finally mixed with 1.8 ml of fetal bovine serum (FBS)
and 0.2 ml of dimethyl sulfoxide (DMSO) before being ali-
quoted into four 0.5 ml tubes and frozen at −80°C. For the
flow cytometry analysis, after washes in PBS-0.5%BSA,
cells were incubated with anti-Calcium Sensing Receptor
Monoclonal Antibody (5C10, ADD; Thermo Fisher Scien-
tific, Rockford, IL, USA) or with negative control Mouse
IgG2a (X 0943; DakoCytomation, Glostrup, Denmark) for
30 minutes on ice. After washes in PBS-0.5%BSA, cells
were incubated with PE-conjugated IgG mouse antibodies









Age, years 60.9 ± 8.3 59.6 ± 5.3 0.42
Gender (female), % 74.0% 72.0% 0.85
Body mass index, kg/m2 27.0 ± 6.0 28.9 ± 8.3 0.32
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(R 0480; DakoCytomation)) for 30 minutes on ice in the
dark. After washes in PBS-0.5%BSA, cells were incubated
with monoclonal CD14 antibodies, human, conjugated
to FITC (130-080-701, MACS; Miltenyi Biotec, Bergisch
Gladbach, Germany) or monoclonal Mouse IgG2a iso-
type control antibodies conjugated to FITC (130-091-
837, MACS; Miltenyi Biotec) for 30 minutes on ice.
After several washes, surface and total CaSR expressions
were analyzed by FACSAria cytometer (BD Biosciences).
When assessing total CaSR expression, detection of intra-
cellular antigens requires a cell permeabilization step prior
to immunostaining. When necessary, cells were therefore
incubated with 100 μl of BD Cytofix/Cytoperm™ (Cat. No.
554722) solution for 20 min on ice and were then washed
twice with BD Perm/Wash buffer (Cat. No. 554723), be-
fore being exposed to both primary and secondary anti-
bodies and assessed for total CaSR expression. Both total
and surface CaSR expression, that is fluorescence inten-
sity, are presented as a percentage. Rheumatoid arthritis
patients were compared to control subjects who served as
reference (fluorescence intensity is equal to 100% in con-
trol subjects).Current smokers, % 16.0% 16.0% 1.00
Diabetes, % 6.0% 12.0% 0.36
Family history of cardiovascular
disease, %
18.0% 20.0% 0.83
Hypertension, % 64.0% 48.0% 0.50
Current use of antihypertensive
therapy, %
44.0% 36.0% 0.50
Systolic blood pressure, mmHg 126.2 ± 17.0 129.3 ± 18.4 0.45
Diastolic blood pressure, mmHg 81.0 ± 12.3 82.6 ± 11.6 0.59
Hypercholesterolemia, % 36.0% 48.0% 0.74
Current use of statins, % 24.0% 16.0% 0.32
Current use of fibrates, % 2.0% 16.0% 0.02
FRS, % 11.4% 13.8% 0.36
RF and/or CCP antibodies, % 86.0% -
Erosive arthritis, % 54.0% -
Duration of disease (years) 12.2 ± 8.5 -
HAQ 0.8 ± 0.7 -
DAS28-hs-CRP 2.5 ± 0.9 -
DAS28-hs-CRP ≤3.2, % 80.0% -
Current methotrexate users, % 90.0% -
Current anti-TNFα users, % 58.0% -
Current NSAIDs users, % 30.0% -
Current corticosteroid users, % 26.0% -
Values are the mean ± standard deviation (SD) (significant results are indicated
in bold). RA, rheumatoid arthritis; FRS, Framingham risk score; RF, rheumatoid
factor; CCP, citrullinated cyclic protein; HAQ, health assessment questionnaire;
DAS28-hs-CRP, disease activity score 28 high-sensitivity C-reactive protein;
TNFα, tumor necrosis factor alpha; NSAIDs, nonsteroidal
anti-inflammatory drugs.Statistical analysis
The sample size was estimated using the nonparametric
method developed by Noether [31]. To demonstrate that
the probability of RA patients with CAC (≥1) has a total
and/or surface CaSR expression greater than RA patients
without CAC (=0) is at least 0.73 with alpha = 5% and
beta = 20%, 25 RA patients with and 25 RA patients
without CAC are necessary. This probability of 0.73 cor-
responds approximately to a Cohen’s effect size of 0.86
[32]. Quantitative variables are expressed as mean ±
standard deviation (SD) or median [range] and qualita-
tive variables are expressed as percentage. Student’s t
test (or Wilcoxon test as appropriate) was used for
comparison of quantitative variables between the two
groups. Chi-square or Fisher’s exact test was used for
comparison of qualitative variables between the two
groups. A multivariate linear regression model was used
for assessment of independent variables correlated with
both surface and total CaSR expression. The correlation
between CaSR expression and laboratory parameters
(Ca, Ph, creatinine clearance, hsCRP, 25 OH vitamin D,
iPTH, total cholesterol, LDL cholesterol, HDL choles-
terol, HIL6, and HTNFα) was studied with the Spear-
man’s rank correlation and a correlation was considered
only when the coefficient was between 0.41 and 1.00 or
between −0.41 and −1.00, with a significant P value. Two-
sided P values <0.05 were considered significant in multi-
variate analysis. SAS software version 9.2 (SAS Institute,
Cary, NC, USA) software was used for all analyses.Results
Clinical and demographic characteristics
The clinical and demographic characteristics of the pa-
tients with RA and the control subjects are shown in
Tables 1 and 2. All patients were of Caucasian descent.
The RA and control groups did not differ significantly in
terms of age (RA: 60.9 ± 8.3; controls: 59.6 ± 5.3), gender
or the prevalence of traditional cardiovascular risk fac-
tors, but the prevalence of diabetes mellitus was twofold
higher among control subjects (12% versus 6%). Moreover,
the mean duration of disease was greater than 12 years,
more than one half of RA patients were treated by TNFα
antagonists. Remission or low disease activity (defined as a







Hemoglobin, g/dl 13.7 ± 1.5 14.3 ± 1.1 0.12
White blood cell, mm3 6264 ± 1797 5624 ± 1650 0.13
Neutrophil, mm3 3604 ± 1458 3232 ± 1283 0.26
Monocytes, mm3 440 ± 145 352 ± 112 0.005
Urea, mmol/l 6.1 ± 1.8 5.2 ± 1.0 0.006
Creatinine, μmol/l 64.6 ± 14.0 66.7 ± 10.6 0.46
Creatinine clearance, ml/mn 97.6 ± 21.0 92.8 ± 15.5 0.26
Calcium, mmol/l 2.31 ± 0.07 2.31 ± 0.09 0.81
Phosphorus, mmol/l 0.94 ± 0.17 0.98 ± 0.15 0.32
Glycemia, mmol/l 4.27 ± 1.08 4.94 ± 0.92 0.01
hs-CRP, mg/liter 3.9 ± 5.2 3.1 ± 4.8 0.54
ESR rate, mm/hour 12.1 ± 10.0 6.3 ± 4.2 0.001
25 OH vitamin D, ng/ml 17.8 ± 8.4 19.9 ± 8.8 0.30
iPTH, pg/ml 43.6 ± 25.0 42.2 ± 18.1 0.41
Total cholesterol, g/l 2.13 ± 0.36 2.29 ± 0.37 0.51
LDL cholesterol, g/l 1.26 ± 0.29 1.36 ± 0.27 0.18
HDL cholesterol, g/l 0.65 ± 0.15 0.61 ± 0.19 0.42
Triglycerides, g/l 1.10 ± 0.51 1.33 ± 0.58 0.09
Values are the mean ± standard deviation (SD) (significant results are indicated
in bold). hs-CRP, high-sensitivity C-reactive protein; ESR, erythrocyte
sedimentation rate; iPTH, intact parathyroid hormone; LDL cholesterol,
low-density lipoprotein; HDL cholesterol, high-density lipoprotein.
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Compared to control subjects, RA patients did not exhibit
higher total CaSR (101.6% ± 28.8 vs. 99.9% ± 22.0) or
surface CaSR (104.6% ± 20.4 vs. 99.9% ± 13.7) expression
in human circulating monocytes. Mean ESR and mean
serum urea were significantly higher in RA patients than
in control subjects (P = 0.001 and P = 0.006, respect-
ively), while monocyte count was higher in RA patients
than in control subjects (P = 0.005) (Table 2). HIL6 levels
were not detectable for 25 control subjects and 45 RA pa-
tients and ranged between 0.97 and 86.8 pg/ml for five RA
patients. HTNFα levels were not detectable for 22 control
subjects and 34 RA patients and were increased in three
control subjects (up to 110.1 pg/ml) and 16 RA patients
(up to 351.0 pg/ml).Table 3 Prevalence of vascular calcification and mean calcific
Site Prevalence of vascular calcification
RA Controls P val
Coronary 64.0% 52.0% 0.31
Aorta 66.0% 64.0% 0.96
RA, rheumatoid arthritis; SD, standard deviation.Vascular calcification
The prevalence of vascular calcification and the CAC
and AAC scores in patients with RA and control sub-
jects are shown in Table 3. Coronary artery calcification
was not more prevalent in patients with RA (64.0%) than
in controls (52.0%) (P = 0.31). The mean CAC score was
205 ± 443 in patients with RA and 134 ± 248 in controls
(P = 0.29). Abdominal aortic calcification was not more
prevalent in patients with RA (66.6%) than in controls
(64.0%) (P = 0.96). The mean AAC score was 1.8 ± 2.0 in
patients with RA and 1.7 ± 1.6 in controls (P = 0.73).
Linear regression analysis and correlations
Spearman’s rank correlation failed to distinguish any sig-
nificant correlation as prespecified between surface and
total CaSR expression and laboratory parameters in RA
patients. Indeed, no association was found between age,
gender or clinical parameters with both surface and total
CaSR expression.
CaSR expression and vascular calcification
Correlations with log-transformed data for CAC and
AAC scores and total and surface CaSR expression were
investigated. While no significant correlation was found
between log-transformed data for CAC score and total
CaSR expression, these data were close to significance
(P = 0.07). No other significant correlations were observed
between log-transformed data for CAC score and surface
CaSR expression (P = 0.87) or between log-transformed
data for AAC score and total and surface CaSR expression
(P = 0.49 and P = 0.67 respectively).
Speculating that total and surface CaSR expression in
human circulating monocytes could be different between
RA patients with mild-to-moderate or severe coronary
artery calcification (CAC = 1 to 199 versus CAC ≥200 or
CAC = 30 to 199 versus CAC ≥200 with a limit of detec-
tion for CAC set at 30 instead of 0), subgroup analysis
was also performed. Total CaSR expression in human
circulating monocytes was significantly higher in RA pa-
tients with severe CAC than in patients with mild-to-
moderate CAC, whether the limit of detection was set at
0 (P = 0.01) or 30 (P = 0.03) (Table 4). No significant
differences were observed when CAC was compared to
surface expression of CaSR on monocytes. A multivari-
ate logistic regression model was used for assessment of
independent variables associated with mild-to-moderateation scores in patients with RA and in controls
Mean ± SD calcification score
ue RA Controls P value
205 ± 443 134 ± 248 0.29
1.8 ± 2.0 1.7 ± 1.6 0.73





Total CaSR expression, % 91.7 ± 20.7 115.3 ± 31.8 0.01
CAC 1–199 CAC ≥200
(n = 21) (n = 11)
Surface CaSR expression, % 104.2 ± 15.0 100.7 ± 8.5 0.41
CAC 30–199 CAC ≥200
(n = 12) (n = 11)
Total CaSR expression, % 91.0 ± 19.4 115.2 ± 31.8 0.03
CAC 30–199 CAC ≥200
(n = 12) (n = 11)
Surface CaSR expression, % 101.8 ± 13.9 100.7 ± 8.5 0.83
Values are the mean ± standard deviation (SD) (significant results are indicated
in bold). CAC, coronary artery calcium; CaSR, calcium-sensing receptor; RA,
rheumatoid arthritis.
Table 5 Logistic regression analysis of mild-to-moderate
























Systolic blood pressure, mmHg 0.87





Total cholesterol, g/l 0.84
LDL cholesterol, g/l 0.77
HDL cholesterol, g/l 0.74
Serum intact PTH 0.33
Serum 25 OH Vitamin D 0.15 0.43
Hemoglobin 0.31
White blood cell 0.57
Neutrophils 0.69
Monocytes 0.04 0.11
Surface CaSR expression 0.84
Total CaSR expression 0.03 0.90
Significant results are indicated in bold. CaSR, calcium-sensing receptor;
hs-CRP, high-sensitivity C-reactive protein; PTH, parathyroid hormone; RF,
rheumatoid factor; CCP, citrullinated cyclic protein; DAS28-hs-CRP, disease
activity score 28-high-sensitivity C-reactive protein; TNFα, tumor necrosis factor
alpha; NSAIDs, nonsteroidal anti-inflammatory drugs; GFR-MDRD, estimated
glomerular filtration rate using the modification of diet in renal disease; LDL
cholesterol, low-density lipoprotein; HDL cholesterol, high-density lipoprotein.
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severe CAC in the multivariate model with odds ratio =
0.034 (95% CI: 0.003 to 0.391; P = 0.007) (Table 5).
Discussion
Calcium-sensing receptor is expressed fairly ubiquitously
and is known to regulate numerous cellular processes ran-
ging from fertilization to cell death [18-20]. Calcium-
sensing receptor should therefore not only be associated
with the G-protein coupled receptor responsible for cal-
cium homeostasis in complex organisms. Moreover, clear
evidence has been published that vitamin D3 concentra-
tions, inflammatory cytokines and particularly secondary
hyperparathyroidism modify CaSR expression throughout
the body [33]. However, apart from in vitro and in vivo ex-
periments, no technique is available to provide clinicians
with an assessment of ‘CaSR status’ in patients. In this
context, we hypothesized that CaSR expression in human
circulating monocytes could represent an accessible bio-
marker in the clinic [28].
As previously demonstrated, CaSR expression is influ-
enced by the direct microenvironment of the cells and
particularly by phosphate, calcium, vitamin D3, inflam-
matory cytokines and chemokines [33]. It can be specu-
lated that CaSR expression in CD14+ monocytes may, to
a certain degree, reflect the influence of circulating blood
on CaSR expression in other cell types in physiological
and pathological conditions. Confirming our previous re-
sults, this study assessed the CaSR status of patients by
flow cytometry in monocytes isolated from total blood.
Moreover, total CaSR expression in human circulating
monocytes was increased in RA patients with severe CAC
versus patients with mild-to-moderate CAC. These results
contrast with those obtained by Malecki et al. [34], who
demonstrated that CaSR expression on the surface of cir-
culating monocytes isolated from atherosclerotic patients
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and type 2 diabetic patients as well as control subjects.
The twofold higher prevalence of diabetic mellitus and the
significant difference in terms of fasting glucose concen-
trations between control subjects and RA patients may
therefore constitute a possible confounder for interpret-
ation of CaSR protein levels. However, taken together,
these studies indicate that CaSR expression is modified
during atherosclerotic processes and that CaSR status
could be a particular valuable marker to be studied on
isolated monocytic cells. A similar discrepancy was ob-
served between our study and that performed in athero-
sclerotic or atherosclerotic and type 2 diabetic patients
in terms of the percentage of CD14+ cells, which were
shown to express surface CaSR. However, direct com-
parison of these studies remains difficult, as different
anti-CaSR antibodies were used, therefore correspond-
ing to different immunoreactivities. Further studies are
needed to clarify this point.
We did not find a higher prevalence and greater burden
of CAC or AAC in RA patients versus age- and gender-
matched controls. Probably due to the limited sample size
of this study and to the higher-than-expected prevalence
and burden of CAC or AAC in control subjects, these ef-
fects were not statistically significant. It should be noted
that the control subjects of our study were older than
those reported in other studies comparing control subjects
versus RA patients [13,14]. Moreover, the majority of RA
patients were in clinical remission or presented low dis-
ease activity with a very low degree of inflammation evalu-
ated by ESR, hs-CRP, IL6 and TNFα. ESR, IL6 and TNFα
concentrations have been demonstrated to be significantly
associated with higher coronary calcium levels in RA
[10,14]. To our knowledge, this is the first study to investi-
gate AAC in RA patients and our results suggest the ab-
sence of any significant difference in AAC score between
RA patients and controls.
In view of the calcium concentration present in vascular
calcification, it was important to clarify whether CaSR
plays a role in this pathological process. Recently, consid-
erable focus has been placed on circulating cells, as circu-
lating monocytes, involved in cardiovascular disease [23]
and CaSR expression has been demonstrated in circulat-
ing monocytes [25,26]. We have previously shown that
CaSR expression in circulating monocytes could repre-
sent an accessible biomarker to monitor an individual’s
‘CaSR status’ under nonpathological conditions [28]. Con-
firming our previous observations, the present study dem-
onstrates, for the first time, a relationship between total
CaSR expression in circulating monocytes and the severity
of CAC in RA. Although this finding needs to be con-
firmed in other pathological conditions in which CaSR
expression is known to be modulated - that is during sec-
ondary hyperparathyroidism in CKD patients - our datademonstrate that the CaSR status of patients can be moni-
tored by following CaSR expression in circulating mono-
cytes over time. It is important to note that, endogenous
agonists of CaSR, such as Mg2+, spermine and cyclic
amino acids, may also modify the net plasma membrane
concentration of the receptor in vivo, without reaching
5 mM Ca2+ [35]. Initially described in HEK cells overex-
pressing CaSR and referred to as the ADIS phenomenon
[36], this process could be of physiological or patho-
physiological relevance, as recently demonstrated by
Hénaut et al. [37]. However, the net increase in plasma
membrane CaSR predominantly results from an increase
in anterograde trafficking via the secretory pathway - at a
constant rate of endocytosis - and the proportion of CaSR
expressed at the plasma membrane may differ significantly
from cell to cell. Further clinical studies must be con-
ducted to more clearly define the physiological role of
CaSR in circulating monocytes. Ionic calcium has been
shown to exert a chemotactic effect on human monocytes
[27]. Whether or not the calcium contained in areas of
vascular calcification are involved in the homing of circu-
lating monocytes via CaSR stimulation remains to be
demonstrated. It can nevertheless be assumed that the cal-
cium gradient adjacent to the vascular wall would be
correlated with the degree of vascular calcification, which
would explain why total CaSR expression is increased in
RA patients with severe CAC scores. Noteworthy, CaSR is
also expressed by VSMCs and CaSR expression was de-
creased in the arteries of patients with CKD compared to
controls [21]. In CKD, the prevalence of vascular calcifica-
tion is also high and modulation of CaSR expression on
VSMCs by calcimimetic agents (R-568) has been recently
demonstrated to effectively delay progression of vascular
calcification and atherosclerosis in uremic apolipoprotein
E-deficient mice and secondary endpoints of the AD-
VANCE study [22,38].
Although this study was designed to assess a potential
link between CaSR expression and vascular calcifications
in RA patients, it presents a number of limitations. First,
with a cross-sectional design, a temporal relationship be-
tween total CaSR expression and coronary artery calcifi-
cation cannot be proven. Second, this study failed to
show that the prevalence of coronary artery calcification
and coronary calcium scores were higher in RA patients
who were in remission for most of them. Finally, the as-
sessment of vascular calcification by spiral computed
tomography allows assessment of calcified atheroscler-
otic plaque, but does not evaluate the other components
of atherosclerotic plaque.
Conclusions
The potential relationship between subclinical atheroscler-
osis assessed by vascular calcification and total and/or sur-
face CaSR expression in human circulating monocytes
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over, our experiments only focused on human circulating
monocytes. Further studies are necessary to investigate
whether simultaneous modification of CaSR expression
is observed in both human circulating monocytes and
VSMCs during the vascular calcification process. CaSR
expression in human circulating monocytes could be
considered to be an emerging tool to monitor CaSR sta-
tus of individuals with different diseases including vas-
cular calcification.
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